profit from every $100 of sales.
$0$100
Insmed
$119.49+2.92% today
-37.7% in 1 year
1-year low $91.881-year high $211.41
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2020 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Insmed sold, what it kept, and what it did with the cash.
Sales went from $245 million in 2022 to $606 million in 2025, with -$1.28 billion of profit last year.
SalesProfit
Insmed vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Insmed | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 21.0× · Fair price | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Insmed's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 164 | 188 | 245 | 305 | 364 | 606 | |
| 125 | 144 | 190 | 240 | 278 | 483 | |
| – | – | -478 | -681 | -787 | -995 | |
| -249 | -382 | -447 | -660 | -819 | -1,178 | |
| -294 | -435 | -482 | -750 | -914 | -1,277 | |
| -3.01 | -3.88 | -3.91 | -5.34 | -5.57 | -6.42 | |
| 75.7% | 76.6% | 77.5% | 78.5% | 76.4% | 79.7% | |
| – | – | -194.9% | -223.1% | -216.3% | -164.0% | |
| -178.9% | -230.6% | -196.3% | -245.6% | -251.2% | -210.5% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 796 | 1,244 | 1,656 | 1,330 | 2,025 | 2,265 |
| Cash | 533 | 717 | 1,074 | 482 | 555 | 510 |
| Total debt | 450 | 800 | 1,154 | 1,178 | 1,122 | 547 |
| Total liabilities | 520 | 833 | 1,568 | 1,662 | 1,740 | 1,526 |
| 276 | 410 | 88 | -332 | 285 | 739 | |
| 98 | 112 | 123 | 140 | 164 | 199 | |
| -28.6% | -25.8% | -29.1% | -62.7% | -46.6% | -73.4% | |
| -106.6% | -105.9% | -547.5% | 225.8% | -320.2% | -172.8% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| -219 | -363 | -400 | -536 | -684 | -935 | |
| 6 | 7 | 10 | 13 | 22 | 33 | |
| -226 | -371 | -410 | -550 | -706 | -968 | |
| Dividends paid | – | – | – | – | – | – |
| – | – | – | – | – | – | |
| 36 | 46 | 58 | 75 | 97 | 153 |
Valuation
- –
- –
- –
- 33.0×
- 43.2×
- –
- –
- -3.7%
- -4.9%
- 0.0%
Profitability
- 79.7%
- -164.0%
- -210.5%
- -139.0%
- -65.3%
- -61.7%
- -130.1%
- -57.0%
- -65.8%
- 101.0%
Growth
- +29.8%
- –
- −37.1%
- –
- +17.5%
Financial health
- –
- 1.06
- 36.1%
- -13.9×
- 4.47
- 4.10
- 0.39
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 4%of 953
Bottom 1%of 877
Top 19%of 871
Bottom 23%of 988
What analysts expect
- Average price target
- $217.11
- Range
- $166.00 – $269.00
- 10 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | -0.76 | -0.90 | +15.6% |
| Feb 19, 2026 | -1.54 | -1.07 | −43.9% |
| Oct 30, 2025 | -1.75 | -1.33 | −31.6% |
| Aug 7, 2025 | -1.70 | -1.30 | −30.8% |
| May 8, 2025 | -1.42 | -1.34 | −6.0% |
| Feb 20, 2025 | -1.32 | -1.17 | −12.8% |
| Oct 31, 2024 | -1.27 | -1.20 | −5.8% |
| Aug 8, 2024 | -1.94 | -1.24 | −56.5% |
News
Why Did Insmed Stock Jump?Yahoo Finance · Oct 30, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
28No pass
Benjamin Graham
35No pass
Philip Fisher
47No pass
Peter Lynch
63Pass
Joel Greenblatt
2No pass
Charlie Munger
28No pass
Terry Smith
41No pass
Questions about Insmed
Is Insmed a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Insmed AI analysis
What does Insmed do?
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. It is in Biotechnology, based in Bridgewater, NJ, United States, with 1,664 employees.
Does Insmed pay a dividend?
No. Insmed does not pay a dividend at the moment.
Is Insmed stock halal?
Yes. Insmed passes our halal screen: its business is permitted and its debt is 2% of its market value, under the 30% limit. How we check
How has Insmed stock done over the past year?
Down 37.7% over the past twelve months, to $119.49. It traded between $91.88 and $211.41 and is 43.5% below its high.
Who are Insmed's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Insmed's.
Prices: daily closes to Nov 10, 2026. Fundamentals: company reports via invest-like data.